Skip to content

Study of Epidural versus Combined Spinal Epidural Anaesthesia for Lower Abdomen and Leg Surgeries

Study of Epidural versus Combined Spinal Epidural Anaesthesia for Lower Abdominal and Limb Surgeries

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021453
Enrollment
60
Registered
2019-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified Health Condition 2: D289- Benign neoplasm of female genitalorgan, unspecified Health Condition 3: N819- Female genital prolapse, unspecified Health Condition 4: D259- Leiomyoma of uterus, unspecified Health Condition 5: C539- Malignant neoplasm of cervix uteri, unspecified Health Condition 6: C402- Malignant neoplasm of long bones of lower limb Health Condition 7: C403- Malignant neoplasm of short bonesof lower limb Hea

Interventions

Intervention1: Combined spinal epidural anaesthesia: Group C will receive combined spinal epidural anaesthesia- after placement of epidural catheter and confirmation with test dose 3 ml of lignocaine

Sponsors

Veer Surendra Sai Institute Of Medical Science And Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria(all) 1. ASA Grade I & II. 2. Age 20 to 60 years of both sex. 3. Undergoing lower limb and lower abdominal surgeries up to 2 hours.

Exclusion criteria

Exclusion criteria: exclusion criteria(none) 1. Infection at the site of injection 2. Spinal abnormalities 3. Neurological disorders 4. Coagulation disorders 5. Drug allergy

Design outcomes

Primary

MeasureTime frame
combined spinal epidural anaesthesia is better in term of onset, duration, efficacy, surgical analgesia, muscle relaxation and hemodynamic response over epidural anaesthesia alone.Timepoint: 1 year

Secondary

MeasureTime frame
Systemic toxicity,adverse effects if any.Timepoint: Will be observed and recorded

Countries

India

Contacts

Public ContactDr Bimal Kishore Panda

Veer Surendra Sai Institute Of Medical Science And Research

drbimalpanda@gmail.com9437175425

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026